Astellas Pharma Inc.
JPX: 4503.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Naoki Okamura
- Employees
- 14,754
- Headquarters
- Tokyo, Japan
- IPO year
- 2000
- Market cap
- ¥4.1T
- Website
- https://www.astellas.com
Loading 4503…
Loading profile data…Frequently asked questions about 4503
What does Astellas Pharma Inc. (4503.T) do?
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution...
Where does 4503.T trade?
Astellas Pharma Inc. (4503.T) trades on the Tokyo Stock Exchange.
What sector is 4503.T in?
Astellas Pharma Inc. (4503.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Astellas Pharma Inc.?
Naoki Okamura is the chief executive officer of Astellas Pharma Inc. (4503.T).
Where is Astellas Pharma Inc. headquartered?
Astellas Pharma Inc. is headquartered in Japan.
Does 4503.T pay a dividend?
Yes — Astellas Pharma Inc. (4503.T) paid a trailing twelve-month dividend of JPY 78.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4503.T go public?
Astellas Pharma Inc. (4503.T) completed its initial public offering in 2000.